Clinical Trials Browser

Phase 1 × selinexor × Other hematologic neoplasm × Clear all

NCT04898894 2026-01-26

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT02091245 2025-12-02

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Phase 1 Active not recruiting

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07094464 2025-07-30

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Phase 1 Completed

34 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03955783 2024-10-26

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Phase 1 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT02299518 2023-06-15

Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Phase 1 Completed

286 enrolled 26 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02403310 2022-10-03

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Phase 1 Completed

Other hematologic neoplasm

Chromosome Aberrations, Leukemia, Leukemia, Myeloid, Acute

NCT02485535 2021-05-13

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03661515 2020-05-20

FLAGINEXOR

Phase 1 Completed

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02573363 2020-04-08

Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02212561 2020-03-26

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02093403 2017-12-08

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute